Semi-Solid Dosage Contract Manufacturing Market Report 2026

Semi-Solid Dosage Contract Manufacturing Market Overview

• Semi-Solid Dosage Contract Manufacturing market size has reached to $17.97 billion in 2025 • Expected to grow to $29.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: Rise In Skin Disease Prevalence Fueling The Growth Of The Market Due To Increasing Demand For Effective Topical Treatments • Market Trend: Strategic Investments Drive Capacity Expansion And Innovation To Meet Growing Demand • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Semi-Solid Dosage Contract Manufacturing Market?

Semi-solid dosage contract manufacturing refers to a specialized pharmaceutical service in which a third-party manufacturer is contracted to produce intermediate-consistency medicinal preparations on behalf of another company. This arrangement allows the contracting company to outsource production while focusing on core activities such as marketing or research. The main types of semi-solid dosage contract manufacturing include topical, transdermal, and oral. Topical semi-solid dosage contract manufacturing involves the external production of formulations such as creams, gels, or ointments that are intended to be applied directly to the skin surface. It uses various materials, such as synthetic, natural, and bio-based, and is used by companies of different sizes, including large-sized companies, medium and small-sized companies, and others. It is applied for dermatology, pain management, hormonal therapy, wound care, ophthalmic disorders, and others, and serves various end uses, including pharmaceutical companies, cosmeceutical companies, and others.

What Is The Semi-Solid Dosage Contract Manufacturing Market Growth Forecast?

The semi-solid dosage contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $29.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing demand for personalized topical therapies, rising investments in advanced formulation technologies, expansion of cosmeceutical outsourcing, growing focus on sustainable excipient usage, increasing regulatory scrutiny on manufacturing quality. Major trends in the forecast period include increasing outsourcing of semi-solid drug manufacturing, rising demand for specialized dermatological formulations, growing adoption of flexible manufacturing lines, expansion of bio-based and natural formulations, enhanced focus on regulatory-compliant production.

Global Semi-Solid Dosage Contract Manufacturing Market Segmentation

1) By Type: Topical, Transdermal, Oral 2) By Material Type: Synthetic, Natural, Bio-Based 3) By Company Size: Large Size Companies, Medium And Small Size Companies 4) By Therapeutic Application: Dermatology, Pain Management, Hormonal Therapy, Wound Care, Ophthalmic Disorders, Other Therapeutic Applications 5) By End Use: Pharmaceutical Companies, Cosmeceutical Companies, Other End Uses Subsegments: 1) By Topical: Creams, Ointments, Gels, Lotions, Pastes, Foams 2) By Transdermal: Transdermal Gels, Transdermal Creams, Transdermal Sprays, Transdermal Emulsions, Medicated Patches 3) By Oral: Oral Gels, Oral Pastes, Oral Suspensions, Oral Emulsions, Oral Jellies

What Is The Driver Of The Semi-Solid Dosage Contract Manufacturing Market?

The high prevalence of skin diseases is expected to fuel the growth of the semi-solid dosage contract manufacturing market going forward. Skin diseases refer to disorders that affect the skin’s appearance or function, often causing symptoms such as irritation, inflammation, or unusual skin growths. Skin diseases are rising due to increasing environmental pollution, which weakens the skin's defense mechanism and leads to greater sensitivity, allergic reactions, and persistent skin problems. Contract manufacturing of semi-solid dosage forms supports the prevention of skin diseases by delivering high-quality, reliably formulated topical treatments that effectively maintain and improve skin health. For instance, in February 2023, according to Cancer Research UK, a UK-based cancer research organization, the average yearly incidence of melanoma skin cancer in the UK is anticipated to grow from around 20,800 cases in 2023–2025 to roughly 26,500 cases by 2038–2040. Therefore, the high prevalence of skin diseases is driving the growth of the semi-solid dosage contract manufacturing industry.

Key Players In The Global Semi-Solid Dosage Contract Manufacturing Market

Major companies operating in the semi-solid dosage contract manufacturing market are The Lubrizol Corporation, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, ANI Pharmaceuticals, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, Madras Pharmaceuticals, Quality CDMO, Axxelent Pharma Science, Tergus Pharma, MedPharm Ltd., Alcami Corporation

Global Semi-Solid Dosage Contract Manufacturing Market Trends and Insights

Major companies operating in the semi-solid dosage contract manufacturing market are focusing on strategic investments to open up new markets and foster innovation. Strategic investments refer to long-term financial decisions made to support and strengthen a company’s core goals, future growth, or competitive position in the market. For instance, in March 2025, LGM Pharma, a US-based provider of semi-solid dosage contract manufacturing services, announced an investment exceeding $6 million to enlarge its manufacturing plant in Rosenberg, Texas. The investment aims to boost production capacity for liquid, suspension, semi-solid, and suppository drug formulations to meet increasing demand for domestic pharmaceutical manufacturing. It aligns with LGM Pharma’s ongoing expansion in prescription drug development, including 505(b)(2) and ANDA programs. The upgrades at the Rosenberg site will support higher output while ensuring full compliance with FDA requirements and current good manufacturing practices. The facility will continue to operate without interruption during the expansion.

What Are Latest Mergers And Acquisitions In The Semi-Solid Dosage Contract Manufacturing Market?

In June 2024, Aterian Investment Partners, a US-based private equity firm, acquired Contract Pharmaceuticals Limited Canada for an undisclosed amount. As a result of the acquisition, CPL is set to advance into a new stage of growth by strengthening its capabilities across people, technology, and processes. The move reinforces its ability to deliver increased value and maintain a strong position as a trusted provider to pharmaceutical companies worldwide. Contract Pharmaceuticals Limited is a Canada-based provider of semi-solid dosage contract manufacturing services.

Regional Outlook

North America was the largest region in the semi-solid dosage contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Semi-Solid Dosage Contract Manufacturing Market?

The semi-solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as process development, formulation support, analytical method development, and quality control testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The semi-solid dosage contract manufacturing market also includes sales of medicated balms, moisturizing agents, lubricating agents, and skin repair agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Semi-Solid Dosage Contract Manufacturing Market Report 2026?

The semi-solid dosage contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the semi-solid dosage contract manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.